Hugel Hosts Taiwan Clinicians as It Expands HA Fillers
Hugel hosted 25 Taiwanese aesthetic-medicine professionals in Korea while expanding its hyaluronic acid filler lineup and pursuing a larger share of Taiwan's botulinum toxin market.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Hugel held its four-day L.E.A.D. academic program from September 16 for 25 aesthetic-medicine professionals from Taiwan. The company is widening contact with local clinicians as it expands its hyaluronic acid filler lineup and targets a 35% share of Taiwan's botulinum toxin market in 2027.
Production Sites Included in the Program
Participants visited production facilities for Hugel's Letybo botulinum toxin and The Chaeum hyaluronic acid filler. The filler is marketed in Taiwan under the name Revolax.
Taiwan Market Strategy
Hugel entered Taiwan in 2019 and is seeking to raise its botulinum toxin market share from about 30% to 35% by 2027. Its clinician program also placed the company's growing hyaluronic acid filler portfolio alongside its toxin business.
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
